Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
A number of stocks jumped in the afternoon session after markets rebounded following a sharp sell-off in the previous trading session as a weaker-than-expected U.S. jobs report fueled speculation that the Federal Reserve will cut interest rates in September. The July Nonfarm Payrolls (NFP) report revealed a significant slowdown in the labor market, with the economy adding only 73,000 jobs, well below the anticipated 110,000. Furthermore, data for May and June was revised downwards, indicating 250,000 fewer jobs were created than initially reported. This weaker economic data has led investors to increase their bets on a potential interest rate cut by the Federal Reserve. According to the CME FedWatch Tool, the probability of a rate cut in September has surged to over 80%. Lower interest rates are generally seen as a positive for growth-oriented stocks, as they can boost economic activity and increase the present value of future earnings, fueling broad-based rallies in sectors like technology.
Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 3.1% in the pre-market session after the company reported second-quarter earnings that surpassed analyst expectations. The company reported second-quarter revenue of $631.9 million and a loss per share of $0.19, both of which came in better than what analysts had forecasted. A key highlight for investors was the significant reduction in net loss, which narrowed to $32.7 million from a substantial $837.7 million in the same quarter of the previous year. However, the report was not without its concerns. Despite beating estimates, total revenue actually declined by 2% year-over-year, signaling persistent growth challenges. Furthermore, Teladoc opted not to raise its full-year guidance, suggesting a cautious outlook. Analyst reactions were mixed, with Cantor Fitzgerald lowering its price target on the stock following the release.
Digital medical services platform Teladoc Health (NYSE:TDOC) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.6% year on year to $631.9 million. The company expects next quarter’s revenue to be around $625 million, close to analysts’ estimates. Its GAAP loss of $0.19 per share was 27.8% above analysts’ consensus estimates.
Digital medical services platform Teladoc Health (NYSE:TDOC) will be reporting results this Tuesday after market close. Here’s what investors should know.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Looking back on online marketplace stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Teladoc (NYSE:TDOC) and its peers.
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media following.
A number of stocks fell in the afternoon session after a broader market sell-off triggered by renewed trade tensions. U.S. stock indices fell after the Trump administration announced intentions to impose a 35% tariff on many goods imported from Canada.
Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 3.5% in the afternoon session after the company received a price target increase from an analyst at Evercore ISI Group. Evercore ISI analyst Elizabeth Anderson raised the firm's price target on the virtual healthcare company to $8.00 from $7.00, while maintaining an "In-Line" rating on the shares.
Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 10.9% in the afternoon session after Citron Research published a report highlighting the company's growth potential following Teladoc's impressive updates at a Goldman Sachs Healthcare conference.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Whether it be online shopping or social media, secular forces are propelling consumer internet businesses forward. These themes have enabled rapid growth for the industry,
which has posted a 1.4% gain over the past six months.
This was a good place to be as the S&P 500 was flat.
